Working… Menu

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03992261
Recruitment Status : Recruiting
First Posted : June 20, 2019
Last Update Posted : August 8, 2019
Information provided by (Responsible Party):
Mayne Pharma International Pty Ltd

Brief Summary:
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Drug: Halobetasol Topical Foam Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Foam, 0.05% in Subjects 12 to Less Than 18 Years of Age With Plaque Psoriasis Receiving Two Weeks of Treatment
Actual Study Start Date : June 14, 2019
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Halobetasol Propionate Foam
2 weeks of application, 2 times daily
Drug: Halobetasol Topical Foam
Other Name: HBP Foam

Primary Outcome Measures :
  1. The proportion of subjects to exhibit adrenal suppression as measured by a cortrosyn stimulation test [ Time Frame: 28 days ]
    A subject is considered to have adrenal suppression evidence if post stimulation lab draw result is less than or equal to 18.0 mcg/100 mL.

  2. The pharmacokinetic properties of HBP foam [ Time Frame: 14 days ]
    Blood samples will be drawn to assess the concentration of HBP absorbed into the body.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Subject is male or non-pregnant female and is 12 to less than 18 years of age
  • Subject has provided written informed assent and was accompanied by the parent or legal guardian at the time of assent/consent signing
  • Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 10% Body Surface Area (BSA)
  • Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit

Key Exclusion Criteria:

  • Subject has spontaneously improving or rapidly deteriorating plaque psoriasis
  • Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis
  • Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function or which exposes the subject to an unacceptable risk by study participation
  • Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation
  • Subject is pregnant, lactating, or is planning to become pregnant during the study
  • Subject is currently enrolled in an investigational drug or device study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03992261

Layout table for location contacts
Contact: Alicia Alton 252-945-0183

Layout table for location information
United States, Florida
Investigative Site 2 Recruiting
Hialeah, Florida, United States, 33012
Contact: Alicia Alton   
United States, Missouri
Investigative Site 1 Recruiting
Saint Joseph, Missouri, United States, 64506
Contact: Alicia Alton   
Investigative Site 11 Recruiting
Batumi, Georgia
Contact: Alicia Alton   
Investigative Site 12 Recruiting
Tbilisi, Georgia
Contact: Alicia Alton   
Investigative Site 13 Recruiting
Tbilisi, Georgia
Contact: Alicia Alton   
Investigative Site 3 Recruiting
Krakow, Poland
Contact: Alicia Alton   
Investigative Site 5 Recruiting
Tarnów, Poland
Contact: Alicia Alton   
Investigative Site 4 Recruiting
Warszawa, Poland
Contact: Alicia Alton   
Investigative Site 9 Not yet recruiting
Dnipro, Ukraine
Contact: Alicia Alton   
Investigative Site 10 Not yet recruiting
Kyiv, Ukraine
Contact: Alicia Alton   
Investigative Site 8 Recruiting
Rivne, Ukraine
Contact: Alicia Alton   
Investigative Site 6 Recruiting
Uzhhorod, Ukraine
Contact: Alicia Alton   
Investigative Site 7 Recruiting
Zaporizhzhya, Ukraine
Contact: Alicia Alton   
Sponsors and Collaborators
Mayne Pharma International Pty Ltd

Layout table for additonal information
Responsible Party: Mayne Pharma International Pty Ltd Identifier: NCT03992261     History of Changes
Other Study ID Numbers: 122-0551-209
First Posted: June 20, 2019    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Physiological Effects of Drugs
Vasoconstrictor Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists